Profiles: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
* [[Media:QIBA FDG-PET Profile v104 06Nov2013.doc|FDG-PET/CT for Response to Cancer Therapy 2013-11-06]] ? | * [[Media:QIBA FDG-PET Profile v104 06Nov2013.doc|FDG-PET/CT for Response to Cancer Therapy 2013-11-06]] ? | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 2]]: Publicly Reviewed=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 2]]: Consensus (Publicly Reviewed)=== | ||
* | * | ||
Revision as of 22:43, 9 November 2016
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed
Stage 2: Consensus (Publicly Reviewed)
Stage 1: Public Comment
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
- CT Volumetry for Advanced Disease 2011-07-08 (Public Comment ended Sept 2011)
See Also
- How to use QIBA Profiles
- QIBA Profile Template may provide additional understanding of the structure, rationale and content of a Profile (turn on Full Markup to see the guidance in the Word comments)
- Committees lists Biomarker Committees developing profiles which may link to DRAFT documents in progress for the next stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.